Format
Items per page
Sort by

Send to:

Choose Destination

Links from

Items: 14

1.

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.

Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, Werth V.

J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007. No abstract available.

2.

Cutaneous lupus erythematosus: diagnosis and treatment.

Okon LG, Werth VP.

Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391-404. doi: 10.1016/j.berh.2013.07.008. Review.

3.

The impact of skin damage due to cutaneous lupus on quality of life.

Verma SM, Okawa J, Propert KJ, Werth VP.

Br J Dermatol. 2014 Feb;170(2):315-21. doi: 10.1111/bjd.12653.

5.

A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus.

Vasquez R, Wang D, Tran QP, Adams-Huet B, Chren MM, Costner MI, Cohen JB, Werth VP, Chong BF.

Br J Dermatol. 2013 Jan;168(1):145-53. doi: 10.1111/j.1365-2133.2012.11106.x. Epub 2012 Sep 13.

6.
7.

Impact of smoking in cutaneous lupus erythematosus.

Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, Werth VP.

Arch Dermatol. 2012 Mar;148(3):317-22. doi: 10.1001/archdermatol.2011.342. Epub 2011 Nov 21. Erratum in: Arch Dermatol. 2012 Dec;148(12):1369.

8.

Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma.

Dutz J, Werth VP.

J Invest Dermatol. 2011 Oct;131(10):1968-70. doi: 10.1038/jid.2011.237.

9.

Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.

Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, Kovarik CL, Luning Prak E, Werth VP.

J Am Acad Dermatol. 2012 Apr;66(4):571-82. doi: 10.1016/j.jaad.2011.01.015. Epub 2011 Aug 6.

10.

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP.

Arch Dermatol. 2011 Nov;147(11):1261-7. doi: 10.1001/archdermatol.2011.191. Epub 2011 Jul 18.

11.

Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Foering K, Goreshi R, Klein R, Okawa J, Rose M, Cucchiara A, Werth VP.

J Am Acad Dermatol. 2012 Feb;66(2):220-8. doi: 10.1016/j.jaad.2010.12.006. Epub 2011 Jul 13.

12.

Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis.

Chang LM, Maheshwari P, Werth S, Schaffer L, Head SR, Kovarik C, Werth VP.

J Histochem Cytochem. 2011 Mar;59(3):336-45. doi: 10.1369/0022155410398000. Epub 2011 Jan 12.

13.

Clinical outcome measures for cutaneous lupus erythematosus.

Albrecht J, Werth VP.

Lupus. 2010 Aug;19(9):1137-43. doi: 10.1177/0961203310370049. Review.

14.

Rheumatic manifestations of skin disease.

Clarke JT, Werth VP.

Curr Opin Rheumatol. 2010 Jan;22(1):78-84. doi: 10.1097/BOR.0b013e328333b9e2. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk